MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck

MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck

Rescue therapies of relapsed/refractory (r/r) Hodgkin’s lymphoma (HL) in the third to sixth-line provide major, yet unresolved problems. The MEPED regimen includes nuclear receptor agonists such as pioglitazone and dexamethasone, which counterbalance HL homeostasis, HL stress response inhibitors, ev...

Full description

Saved in:
Bibliographic Details
Main Authors: Dennis Christoph Harrer, Florian Lüke, Tobias Pukrop, Lina Ghibelli, Albrecht Reichle, Daniel Heudobler
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
relapsed/refractory Hodgkin’s lymphoma
non-oncogene addiction
mTOR
M-CRAC
Hodgkin’s lymphoma tissue editing
anakoinosis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1553331/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1553331/full

Similar Items